NASDAQ : AKBA
Akebia Therapeutics, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 0.7065 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 195.78M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 195.78M |
| Enterprise Value | 239.42M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 277.11M |
| Shares Outstanding | 277.11M |
| Shares Change (YoY) | +15.07% |
| Shares Change (QoQ) | +0.96% |
| Owned by Insiders (%) | 1.75% |
| Owned by Institutions (%) | 41.15% |
| Float | 272.25M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.89 |
| Forward PS | 1.26 |
| PB Ratio | 7.67 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 4.86 |
| P/OCF Ratio | 4.71 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 5.95 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.43 |
| Quick Ratio | 1.30 |
| Debt / Equity | 7.96 |
| Debt / EBITDA | 220.34 |
| Debt / FCF | 4.95 |
| Interest Coverage | -0.34 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -109.38% |
| Return on Assets (ROA) | -1.05% |
| Return on Invested Capital (ROIC) | -1.63% |
| Return on Capital Employed (ROCE) | -3.10% |
| Weighted Average Cost of Capital (WACC) | 6.07% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | -$152,918 |
| Employee Count | 194 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 2.74 |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.82M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -66.36% |
| 50-Day Moving Average | 0.85 |
| 200-Day Moving Average | 1.15 |
| Relative Strength Index (RSI) | 44.92 |
| Average Volume (20 Days) | 8,731,322 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 23.07M |
| Short Previous Month | 22.48M |
| Short % of Shares Out | 8.33% |
| Short % of Float | 8.47% |
| Short Ratio (days to cover) | 3.26 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 219.06M |
| Gross Profit | 178.40M |
| Operating Income | -5.85M |
| Pretax Income | -27.85M |
| Net Income | -29.67M |
| EBITDA | -4.30M |
| EBIT | -5.85M |
| Loss Per Share | -$0.11 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 155.55M |
| Total Debt | 199.19M |
| Net Cash | -43.64M |
| Net Cash Per Share | -$0.16 |
| Equity (Book Value) | 25.02M |
| Book Value Per Share | 0.09 |
| Working Capital | 68.69M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 41.55M |
| Capital Expenditures | -1.29M |
| Depreciation & Amortization | 1.55M |
| Net Borrowing | -5.85M |
| Free Cash Flow | 40.26M |
| FCF Per Share | $0.15 |
Margins
| Measure | Value |
|---|
| Gross Margin | 81.44% |
| Operating Margin | -2.67% |
| Pretax Margin | -12.71% |
| Profit Margin | -13.54% |
| EBITDA Margin | -1.96% |
| EBIT Margin | -2.67% |
| FCF Margin | 18.38% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -15.07% |
| Shareholder Yield | -15.07% |
| Earnings Yield | -15.74% |
| FCF Yield | 20.57% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $3.92 |
| Price Target Difference | 454.42% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | -11.33% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -5.02 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |